{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:46:06Z","timestamp":1789969566856,"version":"4.0.1"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T00:00:00Z","timestamp":1556841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00978","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T08:38:06Z","timestamp":1556872686000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":70,"title":["Current Clinical Trials in Pemphigus and Pemphigoid"],"prefix":"10.3389","volume":"10","author":[{"given":"Kentaro","family":"Izumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/ddg.13637","article-title":"Diagnosis of autoimmune bullous diseases","volume":"16","author":"van Beek","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"B4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/08916934.2011.606447","article-title":"Pemphigoid diseases: pathogenesis, diagnosis, and treatment","volume":"45","author":"Kasperkiewicz","year":"2012","journal-title":"Autoimmunity"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/15665240113136660079","article-title":"Molecular diagnosis in autoimmune skin blistering conditions","volume":"14","author":"Otten","year":"2014","journal-title":"Curr Mol Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2340\/00015555-2611","article-title":"Mortality and cause of death in patients with pemphigus","volume":"97","author":"Kridin","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/bjd.12806","article-title":"Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre","volume":"170","author":"Cai","year":"2014","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3389\/fimmu.2017.01752","article-title":"BP180 is critical in the autoimmunity of bullous pemphigoid","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1172\/JCI60139","article-title":"Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering","volume":"123","author":"Spindler","year":"2013","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1016\/j.ajpath.2014.05.016","article-title":"A desmoplakin point mutation with enhanced keratin association ameliorates pemphigus vulgaris autoantibody-mediated loss of cell cohesion","volume":"184","author":"Dehner","year":"2014","journal-title":"Am J Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"92253","DOI":"10.1172\/jci.insight.92253","article-title":"Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes","volume":"2","author":"Mao","year":"2017","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3389\/fmed.2018.00306","article-title":"Perspective from the 5th international pemphigus and pemphigoid foundation scientific conference","volume":"5","author":"Lee","year":"2018","journal-title":"Front Med."},{"key":"B17","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1046\/j.1365-2133.2003.05209_10.x","article-title":"Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"148","author":"Herrmann","year":"2003","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1046\/j.1365-2230.2003.01283.x","article-title":"Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)","volume":"28","author":"Cooper","year":"2003","journal-title":"Clin Exp Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1046\/j.1365-2133.2003.05580.x","article-title":"Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab","volume":"149","author":"Goebeler","year":"2003","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","article-title":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients","volume":"68","author":"Leshem","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1517\/13543780902832679","article-title":"Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders","volume":"18","author":"Castillo","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"B26","first-page":"51","article-title":"Ofatumumab: a novel monoclonal anti-CD20 antibody","volume":"3","author":"Lin","year":"2010","journal-title":"Pharmgenomics Pers Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri844","article-title":"BAFF: a fundamental survival factor for B cells","volume":"2","author":"Mackay","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.173.2.807","article-title":"B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells","volume":"173","author":"Ng","year":"2004","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/eji.200636914","article-title":"To switch or not to switch\u2013the opposing roles of TACI in terminal B cell differentiation","volume":"37","author":"Salzer","year":"2007","journal-title":"Eur J Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1074-7613(04)00079-2","article-title":"Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF","volume":"20","author":"Lesley","year":"2004","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-0625.2006.00485.x","article-title":"Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases","volume":"16","author":"Matsushita","year":"2007","journal-title":"Exp Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1172\/JCI14121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemicimmune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1136\/annrheumdis-2016-eular.5840","article-title":"THU0313 Double-blind, randomized study of VAY736 single dose treatment in patients with primary sj\u00f6gren's syndrome (PSS)","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann Rheumatic Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1172\/JCI27821","article-title":"Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria","volume":"116","author":"Yoshida","year":"2006","journal-title":"J Clin Invest."},{"key":"B38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12016-009-8153-y","article-title":"High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases","volume":"38","author":"Ishii","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"B40","article-title":"SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases","volume":"130","author":"Blumberg","year":"2017","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/j.jid.2018.03.546","article-title":"FcRn blockade with SYNT001 for the treatment of pemphigus","volume":"138","author":"Werth","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1006\/smim.1998.0123","article-title":"Btk function in B cell development and response","volume":"10","author":"Satterthwaite","year":"1998","journal-title":"Semin Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1002\/eji.1830231210","article-title":"The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages","volume":"23","author":"de Weers","year":"1993","journal-title":"Eur J Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/bies.1062","article-title":"The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species","volume":"23","author":"Smith","year":"2001","journal-title":"Bioessays"},{"key":"B46","doi-asserted-by":"publisher","first-page":"R243","DOI":"10.1186\/ar4086","article-title":"Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus","volume":"14","author":"Hutcheson","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1111\/ajd.12615","article-title":"Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia","volume":"58","author":"Lee","year":"2017","journal-title":"Australas J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.jaci.2018.04.006","article-title":"Regulatory T-cell deficiency leads to pathogenic bullous pemphigoid antigen 230 autoantibody and autoimmune bullous disease","volume":"142","author":"Haeberle","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.3389\/fimmu.2017.01628","article-title":"Regulatory T cells suppress inflammation and blistering in pemphigoid diseases","volume":"8","author":"Bieber","year":"2017","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1681\/ASN.2016111206","article-title":"Cell therapy in kidney transplantation: focus on regulatory T cells","volume":"28","author":"Zwang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/intimm\/dxr020","article-title":"Antigen-independent development of Foxp3+ regulatory T cells suppressing autoantibody production in experimental pemphigus vulgaris","volume":"23","author":"Yokoyama","year":"2011","journal-title":"Int Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/exd.12919","article-title":"Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgaris","volume":"25","author":"Schmidt","year":"2016","journal-title":"Exp Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15171\/jlms.2017.02","article-title":"Relieving pain in oral lesions of pemphigus vulgaris using the non-ablative, non-thermal, CO2 laser therapy (NTCLT): preliminary results of a novel approach","volume":"8","author":"Zand","year":"2017","journal-title":"J Lasers Med Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1468-3083.2010.03610.x","article-title":"Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris","volume":"24","author":"Mignogna","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(05)66829-8","article-title":"Pemphigus","volume":"366","author":"Bystryn","year":"2005","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/jfb9010010","article-title":"Platelet rich plasma: new insights for cutaneous wound healing management","volume":"9","author":"Chicharro-Alcantara","year":"2018","journal-title":"J Funct Biomater"},{"key":"B61","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/wrr.12363","article-title":"Platelet-rich plasma for resistant oral erosions of pemphigus vulgaris: a pilot study","volume":"23","author":"EL-Komy","year":"2015","journal-title":"Wound Repair Regen"},{"key":"B62","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00403-018-1824-x","article-title":"Autologous platelet-rich plasma and triamcinolone acetonide intralesional injection in the treatment of oral erosions of pemphigus vulgaris: a pilot study","volume":"310","author":"El-Komy","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/ni.1613","article-title":"A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses","volume":"9","author":"Volpe","year":"2008","journal-title":"Nat Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.tips.2014.07.006","article-title":"Targeting Th17 cells in autoimmune diseases","volume":"35","author":"Yang","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2230.2009.03704.x","article-title":"Serum cytokines and growth factor levels in Japanese patients with psoriasis","volume":"35","author":"Takahashi","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/BF02684010","article-title":"Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction","volume":"51","author":"Lubberts","year":"2002","journal-title":"Inflamm Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.mehy.2009.10.038","article-title":"Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid","volume":"74","author":"Toosi","year":"2010","journal-title":"Med Hypotheses"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2018.09.003","article-title":"IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid","volume":"96","author":"Chakievska","year":"2018","journal-title":"J Autoimmun"},{"key":"B73","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1067\/mjd.2000.112288","article-title":"Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data","volume":"44","author":"Engineer","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2230.2001.00779.x","article-title":"A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders","volume":"26","author":"Jolles","year":"2001","journal-title":"Clin Exp Dermatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British association of dermatologists' guidelines for the management of bullous pemphigoid 2012","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2310\/7750.2006.00048","article-title":"Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology","volume":"10","author":"Mydlarski","year":"2006","journal-title":"J Cutan Med Surg"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.jid.2018.01.005","article-title":"Intravenous IgG reduces pathogenic autoantibodies, serum IL-6 levels, and disease severity in experimental bullous pemphigoid models","volume":"138","author":"Sasaoka","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3389\/fimmu.2017.01669","article-title":"Anti-idiotypic antibodies against BP-IgG prevent type XVII collagen depletion","volume":"8","author":"Kamaguchi","year":"2017","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","article-title":"The inflammasomes: guardians of the body","volume":"27","author":"Martinon","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.immuni.2013.08.037","article-title":"Mechanisms of NOD-like receptor-associated inflammasome activation","volume":"39","author":"Wen","year":"2013","journal-title":"Immunity"},{"key":"B86","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.1703","article-title":"The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis","volume":"10","author":"Franchi","year":"2009","journal-title":"Nat Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.4049\/jimmunol.1000217","article-title":"Cutting edge: critical role for PYCARD\/ASC in the development of experimental autoimmune encephalomyelitis","volume":"184","author":"Shaw","year":"2010","journal-title":"J Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/BOR.0000000000000088","article-title":"The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis?","volume":"26","author":"Kahlenberg","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4049\/jimmunol.1290031","article-title":"Comment on \u201cInflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus\u201d","volume":"189","author":"Duan","year":"2012","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/rheumatology\/kem372","article-title":"Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project)","volume":"47","author":"Kastbom","year":"2008","journal-title":"Rheumatology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jdermsci.2016.04.009","article-title":"Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid","volume":"83","author":"Fang","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.4049\/jimmunol.1402688","article-title":"Caspase-1-independent IL-1 release mediates blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules","volume":"194","author":"Sadeghi","year":"2015","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management","volume":"54","author":"Amber","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br J Dermatol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1172\/JCI117196","article-title":"92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen","volume":"93","author":"Stahle-Backdahl","year":"1994","journal-title":"J Clin Invest"},{"key":"B101","first-page":"897","article-title":"Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid","volume":"148","author":"Borrego","year":"1996","journal-title":"Am J Pathol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/exd.13382","article-title":"Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid","volume":"26","author":"Bieber","year":"2017","journal-title":"Exp Dermatol"},{"key":"B103","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1034\/j.1398-9995.1999.00170.x","article-title":"Eosinophil activation by eotaxin\u2013eotaxin primes the production of reactive oxygen species from eosinophils","volume":"54","author":"Honda","year":"1999","journal-title":"Allergy"},{"key":"B104","first-page":"1213","article-title":"Bertilimumab Cambridge antibody technology group","volume":"5","author":"Ding","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted therapies for autoimmune bullous diseases: current status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"B106","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.tips.2014.05.007","article-title":"Getting Syk: spleen tyrosine kinase as a therapeutic target","volume":"35","author":"Geahlen","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"B108","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fimmu.2018.00249","article-title":"Whole-genome expression profiling in skin reveals SYK as a key regulator of inflammation in experimental epidermolysis bullosa acquisita","volume":"9","author":"Samavedam","year":"2018","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jid.2016.12.021","article-title":"The leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita","volume":"137","author":"Sezin","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2340\/00015555-3052","article-title":"Unmet needs in pemphigoid diseases: an international survey amongst patients, clinicians and researchers","volume":"99","author":"Lamberts","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3389\/fimmu.2018.01558","article-title":"Therapeutic effect of a novel phosphatidylinositol-3-kinase delta inhibitor in experimental epidermolysis bullosa acquisita","volume":"9","author":"Koga","year":"2018","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.jid.2016.06.619","article-title":"PDE4 inhibition as potential treatment of epidermolysis bullosa acquisita","volume":"136","author":"Koga","year":"2016","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00978\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T08:38:10Z","timestamp":1556872690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00978\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,3]]},"references-count":112,"alternative-id":["10.3389\/fimmu.2019.00978"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00978","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,3]]},"article-number":"978"}}